Rocket Pharmaceuticals Statistics
Share Statistics
Rocket Pharmaceuticals has 91.16M shares outstanding. The number of shares has increased by 0.91% in one year.
| Shares Outstanding | 91.16M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 83.03M |
| Failed to Deliver (FTD) Shares | 1.72K |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 11.90M, so 13.05% of the outstanding shares have been sold short.
| Short Interest | 11.90M |
| Short % of Shares Out | 13.05% |
| Short % of Float | 14.33% |
| Short Ratio (days to cover) | 14.81 |
Valuation Ratios
The PE ratio is -10.25 and the forward PE ratio is -6.12.
| PE Ratio | -10.25 |
| Forward PE | -6.12 |
| PS Ratio | 0 |
| Forward PS | 18.6 |
| PB Ratio | 5.11 |
| P/FCF Ratio | -11.91 |
| PEG Ratio | n/a |
Enterprise Valuation
Rocket Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.8, with a Debt / Equity ratio of 0.05.
| Current Ratio | 7.8 |
| Quick Ratio | 7.8 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.84 |
| Cash Flow / Debt | -7.78 |
| Interest Coverage | -138.48 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -50.16%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.43% |
| Return on Capital (ROIC) | -50.16% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -916.40K |
| Employee Count | 268 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -57.54% in the last 52 weeks. The beta is 1.09, so Rocket Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -57.54% |
| 50-Day Moving Average | 15.75 |
| 200-Day Moving Average | 20.8 |
| Relative Strength Index (RSI) | 30.89 |
| Average Volume (20 Days) | 1.05M |
Income Statement
In the last 12 months, Rocket Pharmaceuticals had revenue of $0 and earned -$245.59M in profits. Earnings per share was $-2.92.
| Revenue | 0 |
| Gross Profit | -7.10M |
| Operating Income | -259.66M |
| Net Income | -245.59M |
| EBITDA | -236.62M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.92 |
Balance Sheet
The company has $55.90M in cash and $25.04M in debt, giving a net cash position of $30.86M.
| Cash & Cash Equivalents | 55.90M |
| Total Debt | 25.04M |
| Net Cash | 30.86M |
| Retained Earnings | -959.37M |
| Total Assets | 393.69M |
| Working Capital | 201.77M |
Cash Flow
In the last 12 months, operating cash flow was -$194.92M and capital expenditures -$16.47M, giving a free cash flow of -$211.39M.
| Operating Cash Flow | -194.92M |
| Capital Expenditures | -16.47M |
| Free Cash Flow | -211.39M |
| FCF Per Share | -2.52 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.29% |
| FCF Yield | -19.3% |
Analyst Forecast
The average price target for RCKT is $52, which is 332.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $52 |
| Price Target Difference | 332.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Jan 5, 2018. It was a backward split with a ratio of 1:4.
| Last Split Date | Jan 5, 2018 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 5.82 |
| Piotroski F-Score | 3 |